KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other financing activities (2021 - 2025)

Nektar Therapeutics has reported Other financing activities over the past 5 years, most recently at $1.3 million for Q3 2025.

  • Quarterly results put Other financing activities at $1.3 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $1.3 million (changed N/A YoY), and the annual figure for FY2025 was $1.2 million, changed.
  • Other financing activities for Q3 2025 was $1.3 million at Nektar Therapeutics, up from $750000.0 in the prior quarter.
  • Over the last five years, Other financing activities for NKTR hit a ceiling of $1.3 million in Q3 2025 and a floor of $750000.0 in Q1 2021.
  • Median Other financing activities over the past 3 years was $750000.0 (2021), compared with a mean of $837666.7.
  • Peak annual rise in Other financing activities hit 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
  • Nektar Therapeutics' Other financing activities stood at $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then skyrocketed by 70.13% to $1.3 million in 2025.
  • The last three reported values for Other financing activities were $1.3 million (Q3 2025), $750000.0 (Q1 2022), and $750000.0 (Q4 2021) per Business Quant data.